Seres Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
7.88
0.83
(11.69%)
Volume:
99,892
52 week range:
6.64 - 30.60
Market Cap:
68.811M
Company Description:
Seres Therapeutics, Inc. engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection. SER-155, a cultivated bacteria microbiome drug, is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases.